Status:
UNKNOWN
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Overactive Bladder Syndrome
Detrusor Overactivity
Eligibility:
FEMALE
Brief Summary
About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects. While beta-3 adrenoceptor agonist, Mirabe...
Eligibility Criteria
Inclusion
- Diagnosis compatible with 2002 ICS for overactive bladder syndrome
- Symptoms persisted for more than 3 months
- Completed pre-treatment urodynamic study
- Has plans for treatment with Mirabegron or Solifenacin due to clinical symptoms
- Patient is willing to cooperate with study including follow up and complete questionnaire surveys
Exclusion
- Has stress urinary incontinence
- Pelvic organ prolapse
- Interstitial cystitis
- Constipation
- Gastroesophageal reflux disease
- Prior failed medical treatment for overactive bladder syndrome
- Uncontrolled hypertension
- Glaucoma
- Currently pregnant
- Using other medications for overactive bladder syndrome
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04693897
Start Date
March 1 2021
End Date
December 31 2022
Last Update
January 27 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.